AG
AVDL

Advisor Group’s Avadel Pharmaceuticals AVDL Stock Holding History

Advisor Group’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$5K Buy
700
+464
+197% +$2.45K ﹤0.01% 4641
2019
Q3 		$1K Sell
236
-544
-70% -$1.36K ﹤0.01% 5077
2019
Q2 		$2K Buy
780
+33
+4% +$57 ﹤0.01% 4948
2019
Q1 		$1K Sell
747
-155
-17% -$351 ﹤0.01% 5031
2018
Q4 		$2K Sell
902
-1,575
-64% -$5.36K ﹤0.01% 4795
2018
Q3 		$11K Sell
2,477
-792
-24% -$4.28K ﹤0.01% 4227
2018
Q2 		$20K Buy
3,269
+93
+3% +$652 ﹤0.01% 3707
2018
Q1 		$23K Buy
3,176
+1,700
+115% +$15K ﹤0.01% 3594
2017
Q4 		$12K Buy
1,476
+63
+4% +$591 ﹤0.01% 3975
2017
Q3 		$15K Buy
1,413
+46
+3% +$439 ﹤0.01% 3722
2017
Q2 		$15K Sell
1,367
-21
-2% -$211 ﹤0.01% 3675
2017
Q1 		$14K Buy
1,388
+1,321
+1,972% +$13.2K ﹤0.01% 3580
2016
Q4 		$1K Sell
67
-37
-36% -$407 ﹤0.01% 4330
2016
Q3 		$1K Buy
104
+2
+2% +$26 ﹤0.01% 4274
2016
Q2 		$1K Buy
+102
New +$1.09K ﹤0.01% 4200

Other funds holding AVDL

BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Advisor Group's AVDL Position: Q4 2019 in Review

Advisor Group increased its Avadel Pharmaceuticals (AVDL) stake by 197% in Q4 2019, buying an estimated $2.45K and bringing the position to 700 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #4641.

Advisor Group first reported a position in AVDL in Q2 2016 and has held it in 15 quarters since. The position peaked at $23K in Q1 2018. 42 funds tracked by Wall St. Rank hold AVDL as of Q4 2019.

  • Advisor Group held 700 shares of Avadel Pharmaceuticals worth $5K as of Q4 2019.
  • Advisor Group bought 464 Avadel Pharmaceuticals shares in Q4 2019, an estimated $2.45K.
  • Avadel Pharmaceuticals made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4641 holding.
  • Advisor Group first reported a position in Avadel Pharmaceuticals in Q2 2016 and has held it in 15 quarters since.
  • Advisor Group's Avadel Pharmaceuticals position peaked at $23K in Q1 2018.
  • 42 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.